Plain-English translation of NCT07371104 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called DWZ2501 (olaparib) — a drug designed to treat advanced ovarian cancer in patients with a BRCA gene mutation. Researchers want to compare this version with another version of the same medication to make sure both versions work the same way in your body. This is an important safety step before the medication becomes widely available.
When a company makes a new version of an existing medication, researchers need to prove that the new version is just as effective and safe as the original. This trial ensures that the two versions perform identically in patients' bodies so doctors can trust either one.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups that take the medication in different orders over two periods. In one period you'd take one version of the medication, and in the other period you'd take the other version, with the researchers measuring how your body processes each one. This helps them confirm that both versions work the same way for you.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
South Korea
Phase
Safety & dosing
Sponsor
Daewoong Pharmaceutical Co. LTD.
Enrollment target
~40 participants
Started
April 2026
Primary completion
March 2027
Age range
19 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in May 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.